Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent.
about
Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53Trial watch - inhibiting PARP enzymes for anticancer therapyNew insight into intrachromosomal deletions induced by chrysotile in the gpt delta transgenic mutation assayFunctional Aspects of PARP1 in DNA Repair and Transcription.Development of synthetic lethality anticancer therapeutics.DNA base excision repair: a mechanism of trinucleotide repeat expansion.PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.Balancing repair and tolerance of DNA damage caused by alkylating agentsPolyADP-ribosylation and cancer.Genomic integration of lambda EG10 transgene in gpt delta transgenic rodents.Genotoxic responses to titanium dioxide nanoparticles and fullerene in gpt delta transgenic MEF cells.Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.Novel poly (ADP-ribose) polymerase 1 binding motif in hepatitis B virus core promoter impairs DNA damage repair.Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
P2860
Q25256778-F8B1CBD4-73B1-4C77-A125-646698A0E806Q26745673-0A4A1BCA-0A7A-4A95-906B-76B16FF32BCCQ28395153-654D5301-DB55-46D3-9B12-1D9ABB852763Q33649584-8ECFCE88-BB49-4251-8F3D-655D62B71E64Q34380368-5F7A208C-4067-44E7-9216-ECF9B649C27FQ35881868-B45AB492-71E0-46D0-A64D-5A26C693639BQ36454901-354E58EA-8034-4BFF-B381-7692C34F9EE1Q36651488-24DA2736-99CB-46F2-B9C9-4E825A9D8272Q36889328-95C7C520-662D-49A1-BE38-A6872793E086Q37031235-E4A0EB82-E801-4950-883B-3FBC43473983Q37116054-65A933AA-FB1C-4B81-9D5D-86157F972819Q37372833-82EF1179-D52A-485C-81C3-DAEE97235463Q39382732-9AE61A6B-7F58-4E6E-8958-3FBB7EAB84A1Q40691174-A4EB3887-7F41-495D-BA5B-AF897C252E7EQ42792442-185DACD4-7A3E-41C0-B0F3-552232FBF50BQ45365306-D22CD7E2-F047-47EF-B9A3-532D600F55DBQ51774005-732C1F35-427E-4714-9A5F-33DF651FAE41Q52597868-A1C8C74F-5F07-46EE-A3D8-F9F277A4F861
P2860
Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@en
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@nl
type
label
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@en
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@nl
prefLabel
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@en
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@nl
P2093
P2860
P356
P1433
P1476
Parp-1 deficiency causes an in ...... ment with an alkylating agent.
@en
P2093
Atsushi Shibata
Hirobumi Teraoka
Hiroshi Suzuki
Hitoshi Nakagama
Ken-Ichi Masumura
Mitsuko Masutani
Nobuo Kamada
Shizuko Kobayashi
Takashi Sugimura
Takehiko Nohmi
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208289
P407
P577
2005-02-01T00:00:00Z
P5875
P6179
1050231688